beclomethasone + fluticasone + salmeterol

This is a combination drug consisting of three active ingredients: beclomethasone, fluticasone, and salmeterol. Beclomethasone and fluticasone are both synthetic glucocorticoid corticosteroids that act as anti-inflammatory agents in the airways by inhibiting multiple types of inflammatory cells and decreasing the production of mediators involved in inflammation. Salmeterol is a long-acting beta-2 adrenergic receptor agonist (LABA) that works as a bronchodilator by relaxing smooth muscle in the airways, leading to improved airflow. This combination would theoretically provide enhanced anti-inflammatory effects along with sustained bronchodilation for the management of asthma or chronic obstructive pulmonary disease (COPD). However, there is no evidence from current sources or clinical guidelines that this specific triple combination (beclomethasone + fluticasone + salmeterol) exists as an approved or marketed product; commonly used combinations include either beclomethasone/formoterol or fluticasone/salmeterol[1][2][3][4][5]. The mechanism of action involves both suppression of airway inflammation and prolonged relaxation of bronchial smooth muscle.